Evidence map›Paper›PMID 41036720›Full record

ArticleJournal of health psychology2026

A qualitative exploration of the experiences of adults with cystic fibrosis unable to benefit from triple combination therapy.

Mulongwe Mwelwa, Christopher Hobson, Steven Stirk, Heledd Lewis, Victoria Samuel

Abstract read
In one paragraph

Article in Journal of health psychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mulongwe MwelwaCardiff University, UK.ORCID 0009-0003-1497-9918
Christopher HobsonCardiff University, UK.
Steven StirkCardiff and Vale University Health Board, Heath Park, UK.
Heledd LewisCardiff University, UK.
Victoria SamuelCardiff University, UK.ORCID 0000-0002-4877-7818

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elexacaftor/Tezacaftor/Ivacaftor (ETI) is a highly effective modulator therapy that has transformed the lives of many people with Cystic Fibrosis (CF). However, limited research has explored the experiences of those not able to benefit from ETI due to genetic factors. Seven adults with CF participated in semi-structured interviews, and data were analysed using Interpretative Phenomenological Analysis (IPA). Four themes emerged: 'feeling forgotten', (the challenges of being in a minority group); 'conflicted emotions', (the emotional impact of comparing one's situation with others); 'fragility of hope', (the journey of hope experienced by participants); and 'remaining on the old CF trajectory', (the ongoing challenges of living with CF). The findings suggest a need for improved communication, psychological and peer support, inclusive media representation and opportunities for active involvement in research and advocacy. Implementing these interventions may help this group feel seen and supported, even as the CF landscape continues to evolve.

Indexed as

AminophenolsBenzodioxolesCystic FibrosisIndolesQuinolonesAdultDrug CombinationsFemaleHumansInterviews as TopicMaleMiddle AgedPyrazolesPyridinesPyrrolidinesQualitative ResearchAminophenolsBenzodioxolesDrug CombinationsIndolesPyrazolesPyridinesPyrrolidinesQuinolonesCystic fibrosisETIinterpretative phenomenological analysisKaftrioTrikaftatriple combination therapy

Identifiers

PMID41036720
PMCPMC13070129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.